Payment overview · 2025
General Payments
$3,929.78
201 reported records · 27 companies
Healthcare provider profile · identity verified
Fazal Rahim, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · PELL CITY, AL · NPI 1811097462
Verified facts
What the public records show
CMS Open Payments records show Fazal Rahim, M.D. received $3,929.78 in general payments during 2025 across 201 reported records.
Eisai Inc. accounted for 10.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Briviact, Hyqvia, Ingrezza, Nurtec Odt, Sunosi, Vumerity.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ubrelvy by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Sunosi by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vumerity by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYREM as an associated drug or biological on 613 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xyrem by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xcopri by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Gammagard Liquid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HYQVIA as an associated drug or biological on 8878 records involving 3983 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Hyqvia by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eisai Inc. | Unresolved — no canonical attribution shown | $414.45 | 10.6% | 16 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $391.59 | 10.0% | 13 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $358.94 | 9.1% | 22 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $327.93 | 8.3% | 20 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $318.88 | 8.1% | 18 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $214.63 | 5.5% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $193.97 | 4.9% | 11 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$192.88 | 4.9% | 10 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $184.68 | 4.7% | 10 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $184.40 | 4.7% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $176.65 | 4.5% | 17 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $172.55 | 4.4% | 8 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $143.97 | 3.7% | 8 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $110.98 | 2.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $95.75 | 2.4% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $89.82 | 2.3% | 4 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.60 | 1.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.75 | 1.4% | 3 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $47.99 | 1.2% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $31.86 | 0.8% | 2 | 2025 |
| Resmed Corp | Unresolved — no canonical attribution shown | $31.56 | 0.8% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $27.91 | 0.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.02 | 0.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.84 | 0.6% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $23.25 | 0.6% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $16.12 | 0.4% | 1 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $15.81 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,906.36 | 199 |
| Education | $23.42 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $391.59 | 13 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $368.86 | 19 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $327.93 | 20 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $264.80 | 14 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $264.80 | 14 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $213.73 | 14 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $193.97 | 11 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $184.68 | 10 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $172.55 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $153.28 | 16 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $153.28 | 16 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $149.02 | 7 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $143.97 | 8 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $133.50 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $110.98 | 5 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $95.75 | 4 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $89.82 | 4 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $56.60 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $55.75 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $35.38 | 4 | 2025 |
Source payment records
|
|||||
| AIRSENSE Normalized: airsense |
Device | Resmed Corp | $31.56 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $27.91 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $11.71 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| HYQVIA hyqvia |
2025 | Hyqvia | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 110 | exact normalized | Medicare Part D |
| Sunosi sunosi |
2025 | Sunosi | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Sunosi open payments reported associated product |
CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059 |
Sunosi · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | XYREM open payments reported associated product |
CMS Open Payments — General Payments 613 supporting records · 589 recipient NPIs · example record 1234298066 |
Xyrem · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
110 | 25 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | HYQVIA open payments reported associated product |
CMS Open Payments — General Payments 8878 supporting records · 3983 recipient NPIs · example record 1223616272 |
Hyqvia · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Primidone | Primidone | 361 | 86 |
| Gabapentin | Gabapentin | 329 | 73 |
| Memantine Hcl | Memantine Hcl | 326 | 81 |
| Topiramate | Topiramate | 290 | 74 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 268 | 65 |
| Clonazepam | Clonazepam | 212 | 32 |
| Pregabalin | Pregabalin | 184 | 42 |
| Donepezil Hcl | Donepezil Hcl | 172 | 39 |
| Levetiracetam | Levetiracetam | 155 | 33 |
| Rizatriptan | Rizatriptan Benzoate | 153 | 45 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 140 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 136 | 28 |
| Baclofen | Baclofen | 132 | 34 |
| Emgality Pen | Galcanezumab-Gnlm | 131 | 17 |
| Meclizine Hcl | Meclizine Hcl | 118 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 117 | 37 |
| Neupro | Rotigotine | 115 | 19 |
| Nurtec Odt | Rimegepant Sulfate | 110 | 25 |
| Nortriptyline Hcl | Nortriptyline Hcl | 108 | 26 |
| Divalproex Sodium Er | Divalproex Sodium | 107 | 32 |
| Oxcarbazepine | Oxcarbazepine | 101 | 23 |
| Aimovig Autoinjector | Erenumab-Aooe | 100 | 11 |
| Buspirone Hcl | Buspirone Hcl | 90 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 23 |
| Doxepin Hcl | Doxepin Hcl | 90 | 31 |
| Trazodone Hcl | Trazodone Hcl | 89 | 21 |
| Lacosamide | Lacosamide | 87 | 13 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 85 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 17 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 81 | suppressed |
| Armodafinil | Armodafinil | 80 | 14 |
| Dexamethasone | Dexamethasone | 78 | 56 |
| Levetiracetam Er | Levetiracetam | 77 | 16 |
| Lamotrigine | Lamotrigine | 73 | 14 |
| Qulipta | Atogepant | 70 | 14 |
| Meloxicam | Meloxicam | 69 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 11 |
| Tramadol Hcl | Tramadol Hcl | 57 | 11 |
| Zonisamide | Zonisamide | 55 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 52 | 13 |
| Alprazolam | Alprazolam | 47 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 15 |
| Sertraline Hcl | Sertraline Hcl | 43 | 11 |
| Ingrezza | Valbenazine Tosylate | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 40 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 37 | suppressed |
| Fentanyl | Fentanyl | 36 | suppressed |
| Hyqvia | Igg/Hyaluronidase,recombinant | 36 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 35 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 34 | suppressed |
| Acetazolamide | Acetazolamide | 33 | 11 |
| Memantine Hcl Er | Memantine Hcl | 32 | suppressed |
| Modafinil | Modafinil | 32 | suppressed |
| Amantadine | Amantadine Hcl | 31 | suppressed |
| Austedo | Deutetrabenazine | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | 11 |
| Diazepam | Diazepam | 27 | suppressed |
| Phenobarbital | Phenobarbital | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 26 | suppressed |
| Ramelteon | Ramelteon | 26 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 25 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Sunosi | Solriamfetol Hcl | 21 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Xcopri | Cenobamate | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Ubrelvy | Ubrogepant | 18 | suppressed |
| Indomethacin | Indomethacin | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 16 | suppressed |
| Xembify | Immune Globulin,gamma(Igg)klhw | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 15 | suppressed |
| Briviact | Brivaracetam | 14 | suppressed |
| Buprenorphine | Buprenorphine | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 14 | suppressed |
| Vumerity | Diroximel Fumarate | 14 | suppressed |
| Epinephrine | Epinephrine | 13 | suppressed |
| Botox | Onabotulinumtoxina | 12 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 12 | suppressed |
| Keppra | Levetiracetam | 12 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Xyrem | Sodium Oxybate | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,929.78 · 201 records | Eisai Inc. | AIRSENSE, BOTOX, Briviact, Fintepla, HYQVIA, Hizentra, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, LUMRYZ, LUNA, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), PONVORY, REXULTI, Rystiggo, Sunosi, TYSABRI, ULTOMIRIS, UPLIZNA, VUMERITY, VYEPTI, VYVGART HYTRULO, WAKIX, XELJANZ, XYWAV, ZAVZPRET, ZEPOSIA | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error